An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options

Trial Profile

An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Tipranavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Expanded access
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 23 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 14 Nov 2012 Planned end date changed from 1 Oct 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top